Despite promising outcomes from early-phase clinical trials (Phases I/II) investigating Menin inhibitors for KMT2A-rearranged AML and other AML subtypes, these agents have not been incorporated into standard clinical practice. This evidence concerns the gene MEN1 and acute myeloid leukemia.